Leukemia

Measuring treatment response is essential to guiding leukemia treatment

Measuring treatment response is essential to guiding leukemia treatment

A measurement of the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may allow for better matching of patients to the optimal intensity of chemotherapy.

Chromosomal rearrangement is key to progress against aggressive infant leukemia

By

Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.

Childhood leukemia study reveals disease subtypes and new treatment options

Childhood leukemia study reveals disease subtypes and new treatment options

By

Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.

Breastfeeding may decrease risk of pediatric acute lymphoblastic leukemia

Breastfeeding may decrease risk of pediatric acute lymphoblastic leukemia

Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).

Presence of protein marks toxicity in leukemia

Presence of protein marks toxicity in leukemia

Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).

Gene variant increases risk and severity of nerve disorder linked to vincristine

By

Children with acute lymphoblastic leukemia with a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.

Reasons behind ibrutinib discontinuation among patients with chronic lymphocytic leukemia

By

A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.

Genetic mutations found in leukemia increase with age

Genetic mutations found in leukemia increase with age

An increase in genetic mutations that could trigger leukemia seems to be a part of aging, according to a new study, but just having cancer-linked DNA doesn't mean the disease will develop.

New opportunity to treat drug-resistant leukemia discovered

New opportunity to treat drug-resistant leukemia discovered

By

A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipients

By

A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.

Test predicts response to treatment for graft-versus-host disease (GVHD)

By

A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.

Risk for leukemia after treatment for early stage breast cancer higher than reported

By

According to results of a new, retrospective study, the risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer is double that previously reported.

Oral inhibitor shows clinical activity in poor-prognosis acute myelogenous leukemia (AML)

By

An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.

New kind of targeted drug is promising for patients with leukemia

New kind of targeted drug is promising for patients with leukemia

By

Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.

Investigational cellular therapy promising for pediatric ALL and for lymphoma

By

Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.

Breast cancer treatment-related leukemia risk higher than thought

Breast cancer treatment-related leukemia risk higher than thought

Among early-stage breast cancer patients who undergo chemotherapy and/or radiation treatment, the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought.

Blincyto now FDA-approved for precursor B-cell acute lymphoblastic leukemia

Blincyto now FDA-approved for precursor B-cell acute lymphoblastic leukemia

The drug, which spurs the body's immune system, has now been approved to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL).

For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease

For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease

Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.

Good news for young patients with a leukemia subtype with poor prognosis

Good news for young patients with a leukemia subtype with poor prognosis

By

For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.

Novel drug safe for patients with leukemia

Novel drug safe for patients with leukemia

By

Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.

For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective

For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective

Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).

High-risk leukemia subtype becomes more common with age

High-risk leukemia subtype becomes more common with age

By

Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.

Weekend hospitalization linked to longer stays for pediatric patients with leukemia

By

Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.

CPI-613 safe and somewhat efficacious for patients with leukemia

CPI-613 safe and somewhat efficacious for patients with leukemia

CPI-613 safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia.

Natural killer cells battle pediatric leukemia

Natural killer cells battle pediatric leukemia

A select team of immune-system cells from patients with leukemia can be multiplied in the laboratory, creating a horde of natural killer cells that can be used to target and destroy the cancer cells.

Major breakthrough in understanding acute lymphoblastic leukemia

Major breakthrough in understanding acute lymphoblastic leukemia

By

By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.

Pediatric patients with leukemia have longer stay if admitted on weekend

Pediatric patients with leukemia have longer stay if admitted on weekend

Weekend admission for pediatric patients with leukemia associated with a longer length of stay.

April Contest

Click here to get started

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs